I was watching 60 minutes when a story caught my attention. It seems this company in San Diego has developed a new drug, Neumune, and the Department of defense has only committed to buying 100,000 doses. This is a drug that has shown strong potential as an anti-radiation drug, and, if approved, would join such old standbys as potassium iodide and Prussian Blue, the latter of which has existed since 1704 (not a typo) and only gained FDA approval 2-3 years ago. The problem here is that's 100,000 doses, with an absolute best case scenario being that drug's ability to treat 100k people, and a real world scenario probably being a fraction, possibly a small fraction, of that. Using the 2000 Census data on the city of Washington, DC, this best case scenario of one dose needed per person would not even treat 1/5 of the population of, at that time, 572,059 people. Expand that to the greater metro area, and you have a ridiculously small percentage that would be treatable. Furthemore expand that to a real-world scenario... Well, you get the picture, and it is far from pretty.
As an interesting side-note, this is my 100th post. At the time I created this blog all those months ago, I never thought I'd actually stick with it and find the process interesting enough to keep it up, much less actively participate in others' blogs. So, hoping this doesn't sound too pretentious, I wish myself a happy 100th post.